前蛋白转化酶枯草溶菌素9抑制剂:阿利库单抗的研究进展

Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors:Research Advances in Alirocumab

他汀类药物被认为是降低低密度脂蛋白胆固醇最有效的药物,从而降低心脑血管疾病的发病率和病死率。然而,他汀类药物不耐受是限制其使用的一个重要原因,尤其是大剂量时。随着前蛋白转化酶枯草溶菌素9的发现,血脂异常的调节有了一个新的方向。阿利库单抗是一种靶向作用于枯草溶菌素9的人源性单克隆抗体,在一系列研究中显示出了良好的前景。现就阿利库单抗的最新研究进展进行综述。

Statins are the most effective medications presently available to reduce low-density lipoprotein cholesterol and decrease the mobility and mortality of cardiovascular and cerebrovascular disease. However, statin intolerance has been a major limitation in the use of st- atins, especially at higher doses. FoUowing the discovery of propvotein convertase subtihsin kexin type 9 （ PCSK9 ）, a new direction has been provided to regulate cholesterol metabolism. Alirocumab, which trade name is Praluent （SAR236553/REGN727）, is a fully human mono- clonal antibody to PCSK9 and has shown good results in a serious of research. The clinical trials research of alirocumab are reviewed in this paper.